Articles

Alpelisib may overcome resistance to CDK4/6 inhibitors in HR-positive/HER2-negative advanced breast cancer patients with shorter exposure to prior CDK4/6 inhibitor treatment. Read More ›

Lack of genetic counseling referrals in women diagnosed with breast cancer contribute to a gap between the need for and completion of genetic testing, reducing access to more personalized therapies for these patients. Read More ›

Alpelisib activity improves real-world progression-free survival in breast cancer patients with PIK3CA mutations when used in combination with fulvestrant compared with fulvestrant alone. Read More ›

Research indicates no significant improvement in breast cancer–specific survival in male breast cancer in the past 30 years. Read More ›

Prognostic understanding may be associated with hospitalization or hospice use depending on how patients were queried about their prognosis and whether oncologists’ estimates were considered. Read More ›

Electronic patient-reported outcome remote monitoring of patients receiving parenteral cancer therapy in routine clinical care is feasible. Office intervention may reduce the need for emergency and inpatient services. Read More ›

Modeling of the ADAURA trial data showed that 3 years of adjuvant osimertinib was more cost-effective than placebo in EGFR-mutated non–small-cell lung cancer (NSCLC). Read More ›

The LC-SCRUM-Asia project analysis indicated that utilization of rapid multigene assays in patients with advanced non–small-cell lung cancer (NSCLC) was associated with short turnaround times and high success rates compared with a targeted assay. Read More ›

Provider adherence to National Comprehensive Cancer Network recommendations and implementation of an automated regimen-level prior authorization is associated with lower cost and more efficient oncology care in patients with non–small-cell lung cancer. Read More ›

The majority of progressing stage IV non–small-cell lung cancer patients with development of resistance to targeted therapies benefit from repeat molecular profiling to detect actionable resistance mechanisms and facilitate clinical trial enrollment. Read More ›